Empiric vancomycin and cefepime narrow to ceftriaxone after a negative MRSA nasal PCR and a susceptible Klebsiella culture in this composite MN650 Unit 6 analysis. Searches like "mn 650 unit 6 assignment example", "mn650 unit 6 sample" and "mn650 unit 6 example" land here.
What a finished MN650 Unit 6 antimicrobial de-escalation analysis looks like
Five pages with a timeline running down the left margin from hour [0] to day [seven]. The opening section justifies the empiric pair against the IDSA and ATS guideline for hospital-acquired pneumonia (Kalil and colleagues, 2016): MRSA coverage and antipseudomonal coverage, both because of intravenous antibiotics within the prior [90] days. Bracketed doses sit in a small table, with vancomycin tied to an AUC target. A second section lists every pending result and the decision it controls. The MRSA nasal PCR returns negative at hour [20]; the paper cites Parente and colleagues (2018) for its high negative predictive value and stops vancomycin. Sputum culture grows Klebsiella pneumoniae susceptible to ceftriaxone at hour [60], and cefepime gives way. A final section sets a [seven]-day total course and states what would reopen the decision.
How a MN650 Unit 6 example is structured
Time structures the analysis, because de-escalation is a sequence of decisions made as information arrives. Each entry on the timeline pairs a result with an action and the evidence for that action, so the paper reads as a chain, not a recap of the final regimen. The empiric section is deliberately brief: breadth was correct on day [one], and the words go to narrowing, which is where the unit places its weight. Two decisions receive fuller treatment. Stopping vancomycin on a negative nasal swab is defended with the predictive-value data and a caveat about settings where MRSA is common. The switch to ceftriaxone is checked against the organism's resistance profile, and a sentence explains why an extended-spectrum beta-lactamase producer would have required a carbapenem instead. Duration follows the 2016 guideline's [seven]-day suggestion, and the reasons that might extend it are named in advance.
Breadth justified once
Intravenous antibiotics within [90] days supply the reason for both MRSA and Pseudomonas coverage. The paper states it briefly, cites the guideline, then moves on, since empiric breadth is rarely where this assignment is contested.
Every pending result, with its consequence
Nasal PCR, sputum culture with susceptibilities, blood cultures and a procalcitonin trend each appear beside the decision they control. A result that would change nothing is identified as such, which keeps the list from inflating.
The swab that ends vancomycin
A negative MRSA nasal PCR, with a negative predictive value above [95] percent in the meta-analysis cited, supports stopping vancomycin at hour [20]. The paper adds that high local prevalence or a positive culture would override the swab.
Narrowing to the organism
Klebsiella susceptible to ceftriaxone lets cefepime go. What the susceptibility report would have to show for that step to be wrong is spelled out, along with the carbapenem an ESBL result would have forced.
Seven days and what stretches them
Total duration counts from the first effective dose. Empyema, bacteremia with a persistent source or a slow clinical response would each reopen the question, and the paper lists them before the course begins rather than improvising later.
Where marks go in MN650 Unit 6
Markers reward narrowing that happens on a stated result, so keeping both drugs for the full course, or narrowing without saying what prompted it, earns the least. Stopping vancomycin without citing the nasal PCR's predictive value, or treating the swab as decisive despite a positive culture, draws a correction. Duration is the other place credit moves: fourteen-day courses defended by habit rather than evidence look dated beside the 2016 guideline. Empiric choices unconnected to risk factors, broad simply because the patient is sick, look unreasoned. Missing the resistance possibility, with no word on what an ESBL-producing organism would change, suggests the susceptibility report was never really read. Vancomycin dosing with no monitoring target, or cultures listed without the hour each result is expected, draws lighter comments.
Get a MN650 Unit 6 example written to your instructions
Culture results, the antibiogram if the case includes one, and the rubric for your MN650 Unit 6 analysis are what the sample needs. It comes back free on a first request, usually within 24-48h, with each narrowing step tied to the result that justified it and whatever would reopen the decision listed beforehand.
MN650 Unit 6 questions, answered
What if the culture grows nothing?
Culture-negative pneumonia still allows de-escalation. The sample would narrow on a negative MRSA swab, clinical improvement and the most likely organisms for the setting, citing the guideline's approach. It would also say what the absence of growth can and cannot rule out, especially when antibiotics started before the specimen was collected.
Should procalcitonin drive the decision?
The 2016 guideline suggests using it together with clinical criteria to support stopping antibiotics, not by itself to decide whether to start. The sample uses a procalcitonin trend as supporting evidence for the duration decision and explains that limit, a sturdier position than treating a single value as a switch.
Can the sample use a different empiric regimen?
Yes. The regimen follows the case, the local antibiogram if one is provided and the risk factors the prompt describes. Piperacillin-tazobactam, meropenem or another antipseudomonal agent may be the right empiric choice elsewhere; the analysis structure, results paired with decisions, stays the same whichever drugs fill it.